| KRAS: From undruggable to a druggable Cancer Target D Uprety, AA Adjei Cancer treatment reviews 89, 102070, 2020 | 207 | 2020 |
| Neoadjuvant immunotherapy for NSCLC: current concepts and future approaches D Uprety, SJ Mandrekar, D Wigle, AC Roden, AA Adjei Journal of Thoracic Oncology 15 (8), 1281-1297, 2020 | 163 | 2020 |
| Ketamine infusion for sickle cell pain crisis refractory to opioids: a case report and review of literature D Uprety, A Baber, M Foy Annals of hematology 93, 769-771, 2014 | 66 | 2014 |
| YouTube as a source of information on cervical cancer J Adhikari, P Sharma, L Arjyal, D Uprety North American journal of medical sciences 8 (4), 183, 2016 | 59 | 2016 |
| MET alterations in NSCLC—current perspectives and future challenges J Remon, LEL Hendriks, G Mountzios, R García-Campelo, SPL Saw, ... Journal of Thoracic Oncology 18 (4), 419-435, 2023 | 46 | 2023 |
| Repotrectinib in ROS1 Fusion–Positive Non–Small-Cell Lung Cancer A Drilon, DR Camidge, JJ Lin, SW Kim, BJ Solomon, R Dziadziuszko, ... New England Journal of Medicine 390 (2), 118-131, 2024 | 38 | 2024 |
| ChatGPT—A promising generative AI tool and its implications for cancer care D Uprety, D Zhu, H West Cancer 129 (15), 2284-2289, 2023 | 36 | 2023 |
| Rovalpituzumab tesirine: A novel DLL3-targeting antibody–drug conjugate BH Lashari, Y Vallatharasu, L Kolandra, M Hamid, D Uprety drugs in r&d 18, 255-258, 2018 | 35 | 2018 |
| Current understanding and future implications of sepsis‐induced thrombocytopenia S Ghimire, S Ravi, R Budhathoki, L Arjyal, S Hamal, A Bista, S Khadka, ... European journal of haematology 106 (3), 301-305, 2021 | 33 | 2021 |
| Challenges in the use of targeted therapies in non-small cell lung cancer J Rivera-Concepcion, D Uprety, AA Adjei Cancer Res Treat 54 (2), 315-329, 2022 | 31 | 2022 |
| Survival trends among patients with metastatic melanoma in the pretargeted and the post-targeted era: a US population-based study D Uprety, A Bista, A Chennamadhavuni, A Niroula, SIM Jafri, A Smith, ... Melanoma Research 28 (1), 56-60, 2018 | 30 | 2018 |
| Renal failure secondary to leukemic infiltration of kidneys in CLL—a case report and review of literature D Uprety, A Peterson, BK Shah Annals of hematology 92 (2), 271-273, 2013 | 26 | 2013 |
| Utilization of surgery and its impact on survival in patients with early stage small-cell lung cancer in the United States D Uprety, L Arjyal, Y Vallatharasu, A Bista, A Borgert, AJ Fitzsimmons, ... Clinical Lung Cancer 21 (2), 186-193. e2, 2020 | 23 | 2020 |
| The effects of HER2 alterations in EGFR mutant non-small cell lung cancer M Nagasaka, V Singh, Y Baca, A Sukari, C Kim, H Mamdani, AI Spira, ... Clinical lung cancer 23 (1), 52-59, 2022 | 20 | 2022 |
| Idelalisib-a PI3Kδ targeting agent for B-cell malignancies YG Hewett, D Uprety, BK Shah Journal of oncology pharmacy practice 22 (2), 284-288, 2016 | 20 | 2016 |
| Occult gastric cancer presenting as hypoxia from pulmonary tumor thrombotic microangiopathy R Mandaliya, S Farhat, D Uprety, M Balla, A Gandhi, R Goldhahn, ... Journal of gastric cancer 14 (2), 142-146, 2014 | 20 | 2014 |
| All that glitters is not gold: the story of rovalpituzumab tesirine in SCLC D Uprety, J Remon, AA Adjei Journal of Thoracic Oncology 16 (9), 1429-1433, 2021 | 19 | 2021 |
| Inhibitor of the nuclear transport protein XPO1 enhances the anticancer efficacy of KRAS G12C inhibitors in preclinical models of KRAS G12C–mutant cancers HY Khan, M Nagasaka, Y Li, A Aboukameel, MH Uddin, R Sexton, ... Cancer research communications 2 (5), 342-352, 2022 | 17 | 2022 |
| The risk of second primary malignancy in patients with stage Ia non-small cell lung cancer: a US population-based study A Khanal, BH Lashari, S Kruthiventi, L Arjyal, A Bista, P Rimal, D Uprety Acta Oncologica 57 (2), 239-243, 2018 | 16 | 2018 |
| SAPPHIRE: Phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer H Borghaei, F de Marinis, D Dumoulin, C Reynolds, W Theelen, ... Annals of Oncology 35 (1), 66-76, 2024 | 15 | 2024 |
